7don MSN
Eli Lilly’s Taltz and Zepbound combo delivers superior results in landmark psoriatic arthritis trial
Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced ...
Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and weight reduction endpoints, according to topline results announced by Eli ...
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...
Clinical Trials Arena on MSN
Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study
These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.
Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz alone in a late-stage trial.
The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results